44.210.21.70
dgid:
enl:
npi:0
FDA Alerts
Hematology
Trending Topics

FDA Approves Selpercatinib for RET-mutant Medullary Thyroid Cancer, NSCLC

Posted on May 11, 2020

The U.S. Food and Drug Administration (FDA) has approved selpercatinib (Retevmo) for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer and the treatment of adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

RET alterations account for the majority of medullary thyroid cancers and a meaningful percentage of other thyroid cancers. For patients living with these cancers, the approval of selpercatinib means they now have a treatment option that selectively and potently inhibits RET,” said Lori J. Wirth, MD, medical director of head and neck cancers, Massachusetts General Hospital Cancer Center, in a press release. “Based on the published data for this new medicine, as well as my personal experience treating patients, this may be a good treatment option.”

 

Read the full press release here.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-